N0290
Nitazoxanide
≥98% (HPLC), pyruvate-ferredoxin oxidoreductase (PFOR) inhibitor, powder
Synonym(s):
NTZ; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H9N3O5S
CAS Number:
Molecular Weight:
307.28
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
259-931-8
MDL number:
Product Name
Nitazoxanide, ≥98% (HPLC)
InChI
1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
InChI key
YQNQNVDNTFHQSW-UHFFFAOYSA-N
SMILES string
CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)[N+]([O-])=O
assay
≥98% (HPLC)
form
powder
originator
Romark
storage temp.
2-8°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
Nitazoxanide has been used:
- to test its anti-viral activity against chikungunya virus
- as an antiprotozoal agent to test its effect on cell viability in various cancer cell lines
- to test its effect on human cytomegalovirus (HCMV) infected human fibroblast HFF cells
Biochem/physiol Actions
Nitazoxanide (NTZ) promotes autophagy by acting on kinase based signaling pathways and acts on mammalian target of rapamycin complex 1 (mTORC1) in Mycobacteria. It has anti-viral property and effectively halts entry and release of chikungunya virus in in vitro studies. NTZ also inhibits Japanese encephalitis virus (JEV) infection in early stages and has the potential to treat other viral infections including dengue, hepatitis B (HBV), coronavirus and human immunodeficiency virus (HIV). It has antineoplastic functionality and may induce apoptosis by promoting proto-oncogene c-Myc inhibition resulting in tumor suppression.
Nitazoxanide is an inhibitor of pyruvate-ferredoxin oxidoreductase (PFOR); Antimicrobial recently found to kill both non-replicating and replicating mycobacteria.
Nitazoxanide is an inhibitor of pyruvate-ferredoxin oxidoreductase (PFOR); FDA approved anti-parasitic drug (2002). Recent work (C & EN Sept. 14, 2009, p. 28) highlights that NTZ kills non-replicating and replicating TB bacteria and no apparent resistance is detected.
Features and Benefits
This compound was developed by Romark. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
Nitazoxanide (NTZ), a thiazolide compound is a antiparasitic drug with structure similar to niclosamide.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis
Lam KYK
PLoS Pathogens, 8(5), 340-351 (2012)
P Patrick Basu et al.
The American journal of gastroenterology, 106(11), 1970-1975 (2011-10-13)
Resistance to standard Helicobacter pylori (HP) treatment regimens has led to unsatisfactory cure rates in HP-infected patients. This study was designed to evaluate a novel four-drug regimen (three antibiotics and a proton pump inhibitor (PPI)) for eradication of HP infection
Vanessa R Anderson et al.
Drugs, 67(13), 1947-1967 (2007-08-29)
Nitazoxanide (Alinia, Daxon, Dexidex, Paramix, Kidonax, Colufase, Annita) has in vitro activity against a variety of microorganisms, including a broad range of protozoa and helminths. Nitazoxanide is effective in the treatment of protozoal and helminthic infections, including Cryptosporidium parvum or
Irit Krause et al.
The Pediatric infectious disease journal, 31(11), 1135-1138 (2012-07-20)
Cryptosporidium parvum is a common cause of diarrhea. In immunocompetent individuals, spontaneous recovery is the rule. In immunocompromised patients, it may cause a serious disease. Data on cryptosporidiosis in children after solid organ transplantation are few. We report on 6
Olivier Vandenberg et al.
The Pediatric infectious disease journal, 31(1), 10-15 (2011-11-19)
Cryptosporidium outbreaks in day-care centers (DCCs) occur commonly. However, controlling spread of infection in these settings is difficult, and data about effectiveness of different control strategies are sparse. In this study, a Cryptosporidium outbreak in a large DCC located in
Articles
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service